Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy

BACKGROUND: Guidelines recommend left ventricular ejection fraction (LVEF) assessments every 3 months for cardiotoxicity monitoring during human epidermal growth factor receptor 2 (HER2) targeted therapy. Evidence in support of this practice is lacking. OBJECTIVES: This study examines the associatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Anthony F., Moskowitz, Chaya S., Lee Chuy, Katherine, Yang, Ji, Dang, Chau T., Liu, Jennifer E., Oeffinger, Kevin C., Steingart, Richard M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584138/
https://www.ncbi.nlm.nih.gov/pubmed/33103123
http://dx.doi.org/10.1016/j.jaccao.2020.03.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584138/
https://www.ncbi.nlm.nih.gov/pubmed/33103123
http://dx.doi.org/10.1016/j.jaccao.2020.03.002

Ejemplares similares